RNA viruses are responsible for a large variety of animal infections. Equine Arteritis Virus (EAV) is a positive single-stranded RNA virus member of the family Arteriviridae from the order Nidovirales like the Coronaviridae. EAV causes respiratory and reproductive diseases in equids. Although two vaccines are available, the vaccination coverage of the equine population is largely insufficient to prevent new EAV outbreaks around the world. In this study, we present a high-throughput in vitro assay suitable for testing candidate antiviral molecules on equine dermal cells infected by EAV. Using this assay, we identified three molecules that impair EAV infection in equine cells: the broad-spectrum antiviral and nucleoside analog ribavirin, and two compounds previously described as inhibitors of dihydroorotate dehydrogenase (DHODH), the fourth enzyme of the pyrimidine biosynthesis pathway. These molecules effectively suppressed cytopathic effects associated to EAV infection, and strongly inhibited viral replication and production of infectious particles. Since ribavirin is already approved in human and small animal, and that several DHODH inhibitors are in advanced clinical trials, our results open new perspectives for the management of EAV outbreaks. Viruses with a RNA genome infect both animals and plants, and dominate the eukaryotic virome by their diversity and deleterious effects 1. Indeed, RNA viral infections are a substantial public health burden affecting humans and domestic animals 2. The pandemic of SARS-CoV-2 coronavirus is the latest and most striking example with thousands of deaths reported so far in different countries in the world. Horses are not an exception, and five of seven equine viruses listed by the World Organization for Animal Health are RNA viruses (OIE). Unfortunately, the veterinary therapeutic arsenal to fight against equine viral diseases is limited, or even not-existent as no antiviral molecule is listed today. During the last years, several studies have used high-throughput screening (HTS) techniques to scan small compound libraries that could impair the replication of equine viruses. These studies were mostly focused on zoonotic viruses like West-Nile virus 3,4. Non-zoonotic equine RNA viruses, such as equine arteritis virus (EAV), were not included in those screenings. Equine arteritis virus (EAV) is a positive-sense single-stranded RNA virus, member of the subfamily Equarterivirinae, member of the family Arteriviridae, genus Alphaarterivirus from order Nidovirales like the Coronaviridae. Equine viral arteritis disease is a recurrent viral infection that causes important economic losses to the horse industry. In most of the cases, EAV infection is subclinical, but some viral strains are virulent and induce fever with body temperature going up to 41 °C, depression, anorexia, edema, nasal discharge, and conjunctivitis. EAV is a virus transmitted by respiratory or venereal routes.
26RNA viruses are responsible for a large variety of animal infections. Equine Arteritis Virus (EAV) is a 27 positive single-stranded RNA virus member of the family Arteriviridae from the order Nidovirales like 28 the Coronaviridae. EAV causes respiratory and reproductive diseases in equids. Although two 29 vaccines are available, the vaccination coverage of the equine population is largely insufficient to 30 prevent new EAV outbreaks around the world. In this study, we present a high-throughput in vitro 31 assay suitable for testing candidate antiviral molecules on equine dermal cells infected by EAV. Using 32 this assay, we identified three molecules that impair EAV infection in equine cells: the broad-spectrum 33 antiviral and nucleoside analog ribavirin, and two compounds previously described as inhibitors of 34 dihydroorotate dehydrogenase (DHODH), the fourth enzyme of the pyrimidine biosynthesis pathway. 35 These molecules effectively suppressed cytopathic effects associated to EAV infection, and strongly 36 inhibited viral replication and production of infectious particles. Since ribavirin is already approved in 37 human and small animal, and that several DHODH inhibitors are in advanced clinical trials, our results 38 open new perspectives for the management of EAV outbreaks. 39 40 41 Keywords: Antiviral activity, equine arteritis virus, dihydroorotate dehydrogenase, pyrimidine 42 biosynthesis inhibitor, ribavirin. 43 44 45 46 47 48
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.